Drug intelligence / Profile preview

DT120 ODT

Development stage: Phase 3
Lead developer: Definium Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

DT120 ODT is a pharmaceutically optimized, orally disintegrating tablet formulation of lysergide (LSD) D-tartrate developed by Definium Therapeutics (formerly MindMed). It utilizes Catalent's Zydis® fast-dissolve technology to deliver the classic serotonergic psychedelic. The drug acts as a partial agonist at the human serotonin-2A (5-HT2A) receptor. It is primarily being developed for the treatment of Generalized Anxiety Disorder (GAD), for which it has received FDA Breakthrough Therapy Designation, and Major Depressive Disorder (MDD). The clinical program includes pivotal Phase 3 studies aimed at addressing serious brain health disorders through central serotonin receptor modulation.

Other names: lysergide tartratelysergide D-tartrateLSD D-tartrate

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on DT120 ODT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DT120 ODT.

Explore the full profile